Norikazu Masuda

Sep 11, 2024 | nature.com | Seock-Ah Im |Javier Cortés |David W. Cescon |Norikazu Masuda |Toshimi Takano |Chiun-Sheng Huang | +6 more

AbstractIn the phase 3 KEYNOTE-355 study (NCT02819518), pembrolizumab plus chemotherapy demonstrated statistically significant and clinically meaningful improvements in progression-free survival (PFS) and overall survival (OS) versus placebo plus chemotherapy among patients with previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC) and programmed cell death ligand 1 (PD-L1) combined positive score (CPS) ≥ 10 tumors.